Kristin Cavallari’s ex-BFF Kelly Henderson has no plans to make up with the star — now or ever.
Kristin Cavallari’s ex-BFF Kelly Henderson has no plans to make up with the star — now or ever.
Boris Johnson’s humiliation in Parliament triggers concerns about UK stability
Here’s everything you need to know about the group H game at Old Trafford
A news report from China.org.cn:
Here’s everything you need to know about the group H game at Old Trafford
The government has authorised the first Covid-19 vaccine after the independent medicines agency approved the Pfizer-BioNTech jab, with officials saying it will be made available “from next week”. This follows months of rigorous clinical trials and a thorough analysis of the data by experts at the MHRA who have concluded that the vaccine has met its strict standards of safety, quality and effectiveness.
The attack in Cametá appears to be a repeat of one carried out in Criciúma city 24 hours earlier.
DocPath, the leader in innovative document software solutions, announces that both its DocPath® Designer v.6 design tool and its powerful DocPath® DocGeneration Engine v6 generation engine allows their customers now to comply with the Payment Services following the Order ECE 1263/2019 that took effect on July 1, 2020, from now on accessible PDF documents can be generated.
George Russell will replace Lewis Hamilton at Mercedes for this weekend’s Sakhir Grand Prix, paving the way for Jack Aitken to make his Formula 1 debut for Williams.
College basketball is coming back to Madison Square Garden this month. In a matchup between the past two NCAA champions, Villanova and Virginia are scheduled to square off Dec. 19 in the heart of New York City, the arena announced Tuesday. Not long after that, the rest of the 2019-20 season was scuttled and the NCAA Tournament was canceled, wiping out an East Regional and the annual NIT championship slated for “The World’s Most Famous Arena.”
(Bloomberg) -- The U.K. became the first western country to approve a Covid-19 vaccine with its regulator clearing Pfizer Inc. and BioNTech SE’s shot ahead of decisions in the U.S. and European Union.The emergency authorization clears the way for the deployment of a vaccine that’s expected to play a significant role in the global effort to halt the coronavirus. Pfizer and its German partner said in November that the shot, relying on novel technology called messenger RNA, was 95% effective in a final analysis of clinical-trial data.The vaccine will be available in Britain from next week, according to a statement from the U.K. government.The U.K. had signaled it would move swiftly in approving a vaccine as part of an operation to protect its population, and doctors across the country were put on standby for a possible rollout. For the government, it’s an opportunity to make up for missteps during the pandemic as Britain’s death toll nears 60,000.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Brokers are increasingly predicting the coronavirus vaccine news last month will herald a strong gain in share prices for a long time, but Liberum today upped the ante, calling it the dawn of a “multi-year bull markets.” It particularly claims small and medium sized UK stocks will benefit, rather than the giant of the FTSE 100.
Britain on Wednesday became the first country in the world to approve the Pfizer-BioNTech vaccine for use and said that it will be rolled out from next week. "The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech’s COVID-19 vaccine for use," the government said. "The vaccine will be made available across the UK from next week."
* U.K. regulator, MHRA, authorizes supply of COVID-19 mRNA vaccine for emergency supply under Regulation 174; Companies are ready to deliver the first doses to the U.K. immediately * First authorization for a COVID-19 vaccine represents a breakthrough scientific achievement to help combat this devastating pandemic * The companies previously signed an agreement to supply a total of 40 million doses to the U.K. with delivery in 2020 and 2021 * U.S. FDA and EU EMA decisions on authorization are expected in DecemberNEW YORK and MAINZ, GERMANY, December 2, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. Pfizer and BioNTech are anticipating further regulatory decisions across the globe in the coming days and weeks and are ready to deliver vaccine doses following potential regulatory authorizations or approvals. The distribution of the vaccine in the U.K. will be prioritized according to the populations identified in guidance from the Joint Committee on Vaccination and Immunisation (JCVI).“Today’s Emergency Use Authorization in the U.K. marks a historic moment in the fight against COVID-19. This authorization is a goal we have been working toward since we first declared that science will win, and we applaud the MHRA for their ability to conduct a careful assessment and take timely action to help protect the people of the U.K.,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world. With thousands of people becoming infected, every day matters in the collective race to end this devastating pandemic.” “The Emergency Use Authorization in the U.K. will mark the first time citizens outside of the trials will have the opportunity to be immunized against COVID-19,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “We believe that the roll-out of the vaccination program in the U.K. will reduce the number of people in the high-risk population being hospitalized. Our aim is to bring a safe and effective vaccine upon approval to the people who need it. The data submitted to regulatory agencies around the world are the result of a scientifically rigorous and highly ethical research and development program.”The MHRA’s decision is based on a rolling submission, including data from the Phase 3 clinical study, which demonstrated a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol. Efficacy was consistent across age, gender, race and ethnicity demographics, with an observed efficacy in adults age 65 and over of more than 94%. In the trial, BNT162b2 was generally well tolerated with no serious safety concerns reported by the Data Monitoring Committee to date. Today’s decision also is based on a review of Pfizer’s and BioNTech’s Chemistry, Manufacturing and Control (CMC) data for BNT162b2.In July 2020, Pfizer and BioNTech announced an agreement with the U.K. to supply 30 million doses of the BNT162b2 mRNA-based vaccine, once authorized for emergency use. That agreement was increased to 40 million doses in early October. The delivery of the 40 million doses will occur throughout 2020 and 2021, in stages, to ensure an equitable allocation of vaccines across the geographies with executed contracts. Now that the vaccine is authorized in the U.K., the companies will take immediate action to begin the delivery of vaccine doses. The first doses are expected to arrive in the U.K. in the coming days, with complete delivery fulfilment expected in 2021. The companies have filed a request for Emergency Use Authorization with the U.S. Food and Drug Administration (FDA) and have submitted the final Conditional Marketing Authorization Application (CA) following rolling submissions with the European Medicines Agency (EMA) and several other regulatory agencies around the world. Manufacturing and Delivery Capabilities Pfizer and BioNTech continue to work in collaboration with governments and Ministries of Health around the world that will distribute the vaccine, subject to country authorization or approval, to help ensure it can reach those most in need as quickly as possible. The companies are leveraging leading vaccine manufacturing and distribution capabilities to quickly scale, manufacture and distribute large quantities of the vaccine at high quality, complementing the mRNA manufacturing expertise of BioNTech gained over almost a decade. Pfizer has a 171-year track record of researching, developing, manufacturing and delivering innovative medicines and vaccines to patients in need. Pfizer and BioNTech are confident in their ability to safely and effectively deliver the vaccine to the people in the U.K. Based on current projections, Pfizer’s and BioNTech’s combined manufacturing network has the potential to supply globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021 (subject to manufacturing capacity and regulatory approval or authorization).Through its existing mRNA production sites in Mainz and Idar-Oberstein, Germany, BioNTech is able to produce mRNA for commercial supply after having already produced the vaccine candidate doses for the clinical trials. BioNTech will also increase its manufacturing capacity in 2021, once a third site in Germany will start manufacturing to provide further capacities for a global supply of the potential vaccine. Critical to distribution in the U.K. will be Pfizer’s manufacturing site in Puurs, Belgium, one of Pfizer’s largest sterile injectable sites. The Puurs site is being used primarily for European supply but will also serve as back up supply to Kalamazoo, Michigan, for the U.S. market. Pfizer has vast experience and expertise in cold-chain shipping and has an established infrastructure to supply the vaccine worldwide, including distribution hubs that can store vaccine doses for up to six months. The company’s distribution is built on a flexible just-in-time system that can ship the frozen vials quickly to designated points of vaccination at the time of need. So, this will minimize the need for long term storage anywhere. Vaccination in a pandemic situation is expected to be rapid, with high demand, and we do not expect that the product will need to be stored at any location for more than 30 days. To assure product quality, the companies have developed specially designed, temperature-controlled shippers for the BNT162b2 vaccine candidate, which can maintain recommended storage conditions (-70°C ±10°C) for extended periods of time without any additional equipment but dry ice. The shipper can maintain temperature for 10 days unopened which allows for transportation to markets globally. Once open, a vaccination center may use the specially designed shippers as a temporary storage solution to maintain the recommended storage conditions (-70°C ±10°C) up to 30 days with re-icing every five days in accordance with the handling instructions. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment 24 hours a day, seven days a week. Once thawed, the vaccine vial can be stored for up to five days at refrigerated (2-8°C) conditions.From the start of the research program earlier this year, Pfizer and BioNTech have successfully supplied and distributed their investigational vaccine to more than 150 clinical trial sites across the U.S., as well as Europe, Latin America and South Africa reaching approximately 44,000 participants. Based on their collective experience, the companies believe in their capability to distribute the vaccine globally upon approval or authorization. BioNTech will hold the regulatory authorization in the U.K., and, if granted, in the U.S., the EU, Canada and other countries. Pfizer will have the commercialization right worldwide with the exception of China, Germany and Turkey.About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Pfizer Disclosure Notice The information contained in this release is as of December 2, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, a temporary authorization for emergency use in the U.K., regulatory submissions, including a pending request for Emergency Use Authorization in the U.S. and rolling submissions with the EMA and several other regulatory agencies around the world, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply), that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial or in larger, more diverse populations upon commercialization; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when any other biologics license and/or Emergency Use Authorization applications may be filed in any jurisdictions for BNT162b2 or any other potential vaccine candidates; whether and when any applications that may be pending or filed for BNT162b2 may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if approved, whether it will be commercially successful; whether and when the U.K. temporary use authorization may be superseded by the grant of a Marketing Authorisation; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine candidate’s ultra-low temperature formulation and attendant storage, distribution and administration requirements, including risks related to handling after delivery by Pfizer; the risk that we may not be able to successfully develop non-frozen formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.About BioNTech Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de. BioNTech Forward-looking Statements This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.Pfizer Contacts:Media Relations Andy Widger +44 7970 149098 firstname.lastname@example.orgInvestor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.comBioNTech Contacts:Media Relations Jasmina Alatovic +49 89 62 81 75 46 Media@biontech.deInvestor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 Investors@biontech.de
(Bloomberg) -- Asian stocks traded mixed Wednesday while European and U.S. futures edged lower as investors mulled revived aid talks in Washington and progress on coronavirus vaccines. The dollar held a slide to a more than two-year low and oil extended losses.Shares outperformed in South Korea, edged higher in Japan and fell in Hong Kong, where China’s No. 2 smartphone maker Xiaomi Corp. dropped the most ever after disclosing a share sale. S&P 500 futures slipped after the gauge closed up more than 1%.The offshore yuan erased a gain after a report that President-elect Joe Biden won’t immediately remove tariffs on Chinese goods. Biden told the New York Times he’ll leave the phase-one trade deal with China in place while he reviews U.S. policy toward the Asian nation in consultation with key allies.Oil slid as tensions between OPEC members heightened uncertainty over the group delaying its planned output increase. Gold held an advance, while Bitcoin retreated after almost reaching $20,000 for the first time. Benchmark Treasury yields stayed above 0.9%.After a record month for global stocks, the rally that’s been fueled by vaccine breakthroughs looks like it may be cooling. Pfizer Inc. and partner BioNTech SE have sought regulatory clearance for their Covid-19 vaccine in the European Union and BioNTech said it could start shipping the first doses “within hours” after approval. Still, the pandemic continues to gather strength across the U.S. and policy makers are warning about the economic implications.“The question is how much is already priced in, and is the upside therefore limited?” Esty Dwek, head of global market strategy at Natixis Investment Managers Solutions, wrote in a report. “As we look to 2021, the outlook is one of improvement and leaving behind the chaos of the pandemic. Still, a number of risks remain.”Congressional efforts to pass additional coronavirus relief in the U.S. crept ahead Tuesday as House Speaker Nancy Pelosi presented a fresh Democratic proposal and Senate Majority Leader Mitch McConnell floated a revision of his smaller plan to fellow Republicans.Federal Reserve Chairman Jerome Powell cautioned lawmakers that the U.S. economy remains in a damaged and uncertain state during testimony at a Tuesday hearing before the Senate Banking Committee. In Australia, the central bank governor said a recovery is underway but remains patchy.These are some key events coming up:Fed’s Powell testifies before Congress again on Wednesday.The U.S. employment report on Friday is expected to show more Americans headed back to work in November, though at a slower pace than October.Here are some of the main moves in markets:StocksS&P 500 futures fell 0.2% as of 6:53 a.m. in London. The S&P 500 Index rose 1.1% on Tuesday.Topix index rose 0.3%.Hang Seng lost 0.1%.Australia’s S&P/ASX 200 index was little changed.Kospi index gained 1.6%.Shanghai Composite was little changed.Euro Stoxx 50 futures fell 0.3%.CurrenciesThe Bloomberg Dollar Spot Index was steady after declining 0.7% Tuesday.The yen fell 0.1% to 104.47 per dollar.The offshore yuan was at 6.5541 per dollar.The euro was little changed at $1.2067, after rising over 1% Tuesday.BondsThe yield on 10-year Treasuries was at 0.92%, after climbing nine basis points on Tuesday.Australia’s 10-year bond yield jumped to 0.98%.CommoditiesWest Texas Intermediate crude fell 0.8% to $44.22 a barrel.Gold fell 0.1% to $1,813.17 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Training camps pushed back to January as most opt for low-key COVID-proof December
Habibou Sore had to pause for breath as she ran barefoot from the approaching gunmen. Attacks by Islamist groups with links to al Qaeda and Islamic State have killed thousands of people this year in Africa's Sahel region, an arid belt to the south of the Sahara Desert.
No. 12 Indiana is moving forward with a new quarterback but the same mindset heading into Saturday's Big Ten Conference showdown at No. 16 Wisconsin. The announcement that starting Indiana quarterback Michael Penix Jr. was done for the year with a torn ACL on Monday was tough for players and coaches to accept, but the Hoosiers (5-1) are prepared to rally around his replacement, sophomore quarterback Jack Tuttle. "Setbacks and adversity is part of this life," Indiana coach Tom Allen said.
My mother has dementia but Vodafone won't cancel her mobileThey refused to discuss her account because I couldn’t give passwords she can no longer remember
DocuBay VOD service joins the Bango circleCAMBRIDGE, United Kingdom, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Bango (AIM: BGO), the global platform for data-driven commerce, has partnered with DocuBay, to distribute memberships for IN10’s international global VOD platform, DocuBay. Focused on high quality documentary content, DocuBay offers customers global membership to its Video-On-Demand platform. Under this agreement, Bango Resale technology and partnerships will power DocuBay’s growth plans to increase availability to more audiences around the world, expanding its global presence and growing its user base.Through this Bango partnership, telecommunications companies, retailers and other mass market consumer businesses can now offer their users bundled subscriptions to DocuBay’s entertainment suite, using Bango Resale technology. Bundling desirable products with first-party services creates powerful offers that attract and retain more customers.DocuBay, the premium membership Video-On-Demand streaming service by IN10 Media Network, provides an exclusive catalog of documentaries in over 180 countries, in a wide variety of genres on several platforms and devices, including iOS / App Store, Android / Google Play Store , Apple TV and Fire TV, Roku, LG, Samsung TVs and through the DocuBay website.Girish Dwibhashyam, Vice President – Strategy, DocuBay said, “The streaming business has seen a dramatic shift this year, with increased focus on expanding ways to reach the end consumer. DocuBay’s unique value proposition is waiting to be explored by millions of internet users worldwide, with its vast library of premium international documentary content which we believe is sure to see more uptake. We look forward to widening access to this valuable content through our partnership with Bango.”Jim Plimmer, SVP Payment Product Strategy & Sales commented: “Building desirable content and service options is proven to make first party services more attractive and deepen engagement. Consumers get more choice, and for resale partners their own products become more attractive and sticky, it’s win-win. Bango is excited to work with DocuBay to take its documentary content to more people globally, especially important in the current climate.”About BangoApp developers, stores and payment providers cross the threshold into the Bango ecosystem to converge, grow and thrive. By bringing businesses together and powering e-commerce with unique data-driven insights, Bango delivers new business opportunities and new dimensions of growth for customers around the world. Being inside the Bango circle means global merchants including Amazon, Google and Microsoft can work together with payment partners from Africa to the Americas, accelerating the performance of everyone on the inside.Bango. Think inside the circle. For more information, visit www.bango.com.About DocuBayHeadquartered in Mumbai, DocuBay is a global membership VOD platform exclusively designed to stream premium international documentaries. Specializing as a factual entertainment video service, DocuBay features content from all corners of the globe in a variety of categories. Available in 170+ countries, DocuBay is available on platforms including the Apple App Store, Google Play Store, Fire TV, Roku, Apple TV and Samsung TVs, with additional platforms on the way. Join the Tribe on www.DocuBay.comAbout IN10 Media:IN10 Media Network is a parent company to diverse businesses in the media and entertainment industry. With deeply entrenched roots in the creative community and a long association with premium content, the businesses in its folds—including EPIC TV, ShowBox, Filamchi, Gubbare, EPIC ON, DocuBay, Juggernaut Productions and Platanista Games – covering every aspect of the content life-cycle across platforms. Led by entrepreneur Aditya Pittie, IN10 Media Network has its efforts focused on building world-class brands. For more details, visit https://www.in10media.com/Media contact:Anil Malhotra, CMO email@example.com Tel: +44 7710 480 377
HOYA Vision Care has selected Nomads as their global creative agency, following a pitch against agencies from London, Germany and Amsterdam.